Veliflapon

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameVeliflapon
Drug Alias Nameveliflaponum维夫拉朋DG-031Bay-x-1005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action5-lipoxygenase activating protein inhibitors
Targets5-lipoxygenase activating protein
Therapy Area/IndicationsAcute Coronary Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDecode Genetics
Active IndicationsN/A
Inactive IndicationsAcute Coronary Syndrome

Other Information

ATC CodeN/A
Related LinksKEGG